الفهرس 
Chronic liver diseaseOnly 14 pages are availabe for public view
 |  | from | 169 |  |  |
| | | from | 169 | | |
Abstract
Cirrhosis is a common cause of death, it refers to a progressive,
diffuse, fibrosing, nodular condition that disrupts the entire normal
architecture of the liver. Portal hypertension is the leading cause of
morbidity and mortality in liver cirrhosis. Ascites is the most common
complications of cirrhosis and is associated with increased risks of other
complications such as hepatorenal syndrome.Hepatorenal
syndrome (HRS) is a functional form of acute kidney injury (AKI)
associated with advanced liver cirrhosis or fulminant hepatic failure.
Several studies have reported increased U-II levels in patients with
chronic liver diseases.Urotensin II has been shown to be higher in patients
with more advanced alteration of hepatic function and particularly in those
that will progress to the hepatorenal syndrome.
The current study aimed to measure serum Urotensin II levels in
different grades of chronic liver diseases (patients with ascites and without
ascites) to reveal if it has a role in pathogenesis and progression of the
disease and whether it can be used for early diagnosis of hepatorenal
syndrome or not.
This study was carried out on 40 patients with cirrhosis, and 10
apparently healthy volunteers. The subjects were categorized into; 20
patients having cirrhosis with ascites and 20 patients having cirrhosis
without ascites.
All patients were subjected to:full history taking, thorough clinical
examination, abdominal ultrasonography, endoscopy for varicies,
laboratory investigations including( complete blood count, erythrocyte
sedimentation rate, liver function tests,kidney function tests (urea and
creatinin),lipid profile, fasting blood sugar, coagulation profile (PT and
ASSESSMENT OF UROTENSIN II IN PATIENTS WITH CHRONIC LIVER DISEASES WITH AND WITHOUT ASCITES
-123-
APTT), viral markers (HBsAg , presence or absence of HCV Ab), and
serum urotensin II immunoreactivity is measured using a commertial
ELISA kit).
The results of the study revealed that:
1-The gender was statistically non-significantly different between group I
(ascitic) and group II (non ascitic).
2-The age was statistically non-significantly different between group I
(ascitic) and group II (non ascitic).
3-WBCs, RBCs, Hb, HCT, MCV and ESRwere statistically nonsignificantly
different between group I (ascitic) and group II (non
ascitic), while platelets count was significantly lower in ascitic
patients when compared to non ascetic patients.
4-AST, T.protein, S.albumin, and ALP were statistically nonsignificantly
different between group I (ascitic) and group II (non
ascitic), while ALT and D.bilirubin were significantly higher in
ascitic group than non ascitic group.
5-serum Creatinine was statistically non-significantly different between
group I (ascitic) and group II (non ascitic), while serum urea was
significantly higher in ascetic group than in non-ascitic group.
6-cholesterol, TG, LDL and HDL were statistically non-significantly
different between group I (ascitic) and group II (non ascitic).
7-PT, INR and APTT were statistically non-significantly different
between group I (ascitic) and group II (non ascitic).
8-Hepatorenal syndrome was statistically non-significantly different
between group I (ascitic) and group II (non ascitic).
9-HBsAg and HCV ab were statistically non-significantly different
between group I (ascitic) and group II (non ascitic).
10-Esophageal variceswas statistically highly significantly different
ASSESSMENT OF UROTENSIN II IN PATIENTS WITH CHRONIC LIVER DISEASES WITH AND WITHOUT ASCITES
-124-
between group I (ascitic) and group II (non ascitic).
11-Ultrasonic findings of kidneywas statistically significantly different
between group I (ascitic) and group II (non ascitic).
12-Splenomegaly was statistically non-significantly different between
group I (ascitic) and group II (non ascitic).
13-Ultrasonic findings of the liver was statistically non-significantly
different between group I (ascitic) and group II (non ascitic).
14-Urotensin II level was statistically non-significantly different between
Cirrhotic patients and controls, Cirrhotics with ascitis and cirrhotics
without ascitis, Cirrhotics with hepatorenal synd. and cirrhotics
without hepatorenal synd., HCV ab +ve patients and HCV ab -ve
patients, and HBVs Ag +ve patients and HBVs Ag -ve patients.
15-Urotensin II level has significant +ve correlation with urea in group II
(non ascitic) patients and has non-significant +ve correlation with
other parameters in both groups.